About Apathy

Dr. Meg Robertson

June 12, 2025



600 1st Ave Ste 330
PMB 100974
Seattle, Washington 98104-2246 US
(541)630-3888; FAX: (360) 251-0821
Website: www.ctrrinc.com
Nonsecure email: trauma.resilience.research@gmail.com
https://orcid.org/0009-0008-0661-3461

Abstract

Apathy is a pervasive neuropsychiatric syndrome defined by diminished motivation, emotional indifference, and reduced goal-directed behavior. Highly prevalent in neurodegenerative disorders such as Alzheimer's and Parkinson's disease, apathy significantly affects patient quality of life, caregiver burden, and treatment outcomes. This essay synthesizes current research on the clinical definitions, neural mechanisms, assessment tools, and interventions for apathy, while also discussing sociocultural and ethical implications. With a focus on translating interdisciplinary research for practical use, the paper addresses the unique needs of academics, clinicians, and clients.

Keywords: apathy, motivation, neuropsychiatry, assessment, intervention, depression, dementia

About Apathy

Apathy, despite its prevalence and impact, remains an underrecognized and often misunderstood clinical and social problem. Traditionally mistaken for laziness or simple disinterest, apathy is increasingly viewed as a multidimensional neuropsychiatric syndrome marked by a significant reduction in motivation, goal-directed activity, and emotional engagement (Mehak et al., 2023; Miller et al., 2021). This syndrome is especially prominent in neurodegenerative diseases, but also appears in psychiatric, medical, and social contexts (Lanctôt et al., 2023; Nsor & Brown, 2024). For academics and clinicians, distinguishing apathy from related constructs like depression and anhedonia is crucial for appropriate diagnosis and intervention. For clients and their families, understanding apathy as a syndrome—not a personal failing—can relieve stigma and facilitate help-seeking (Manera et al., 2020).

Clinical Definitions and Distinction from Depression

Apathy is often defined as a quantitative reduction in goal-directed behavior compared to an individual's previous level of functioning, encompassing behavioral, cognitive, emotional, and social dimensions (Miller et al., 2021). Unlike mood disorders that center on emotional valence, apathy revolves around the motivational system. The Diagnostic Criteria for Apathy in Neurocognitive Disorders (DCA-ND), developed by Miller et al. (2021), establish three core dimensions: diminished initiative, diminished interest, and diminished emotional responsiveness. These criteria are useful in differentiating apathy from overlapping constructs such as depression and anhedonia (Lanctôt et al., 2023).

Apathy is not limited to psychiatric illnesses but occurs across a spectrum of neurological conditions and even in somatic disorders such as chronic stroke and neuroinflammatory diseases (Pallucca et al., 2024). Furthermore, apathy can exist in otherwise healthy individuals,

manifesting in the form of sociopolitical disengagement and motivational stagnation, as documented in sociological and political science literature (Zhelnina, 2020; Nooruddin & Rudra, 2025).

The diversity in apathy's manifestations necessitates a careful distinction between primary apathy—arising from disruptions in frontal-subcortical circuits—and secondary apathy—stemming from psychological distress, medication side effects, or environmental factors (Padala et al., 2020). The prevalence rates vary considerably, with estimates as high as 70% in Alzheimer's disease and 40% in Parkinson's disease (Ma, 2020; Morris et al., 2023). These findings underscore apathy's status as not merely a comorbid symptom but a standalone clinical syndrome demanding targeted attention.

Apathy as a Clinical Syndrome

Apathy is formally defined as a persistent reduction in motivation relative to an individual's baseline, manifesting as diminished initiative, decreased emotional responsiveness, and reduced engagement in activities or relationships (Miller et al., 2021). Unlike depression, which centers on pervasive sadness, hopelessness, or self-criticism, apathy is marked by an absence of drive or concern, often without notable emotional distress (Lanctôt et al., 2023).

Differentiation from Depression

Clinically, distinguishing apathy from depression is essential. Depression typically features affective suffering—sadness, guilt, insomnia, and suicidality—whereas apathy centers on a lack of motivation and initiative, even in the absence of negative mood (Lanctôt et al., 2023; Ma, 2020). For example, patients with dementia may show apathy as a loss of interest in personal care or social interaction, but without the dysphoria or pessimism characteristic of depression. This distinction is crucial for intervention, as apathy often fails to respond to

antidepressants and may require distinct psychosocial or pharmacological approaches (Padala et al., 2020; Plant et al., 2024).

Implications for Clients and Families

For clients and families, understanding these distinctions can validate their experience and reduce self-blame. Recognizing apathy as a syndrome can encourage earlier help-seeking and reduce the frustration that arises when traditional depression treatments do not work (Manera et al., 2020; Silva et al., 2021).

Neurobiological Mechanisms

The pathophysiology of apathy is deeply rooted in disruptions to specific brain circuits, particularly those involving the frontal-subcortical pathways. These circuits are responsible for executive functioning, motivation, and emotional regulation. The dorsolateral prefrontal cortex (DLPFC), anterior cingulate cortex (ACC), orbitofrontal cortex (OFC), and the ventral striatum—especially the nucleus accumbens—have all been implicated in the development of apathy (Mehak et al., 2023; Morris et al., 2023). Neuroimaging studies have consistently shown that structural or functional abnormalities in these regions correlate with higher apathy scores across multiple conditions, including Alzheimer's disease, Parkinson's disease, and cerebrovascular disease.

The nucleus accumbens, a key node in the brain's reward system, plays a particularly critical role in modulating motivational salience and reinforcement learning. Morris et al. (2023) demonstrated that functional connectivity deficits between the nucleus accumbens and cortical regions in patients with Parkinson's disease precede the onset of clinically observable apathy. These findings suggest that apathy may develop prior to other cognitive or affective symptoms and could serve as an early biomarker in neurodegenerative disorders.

Neurotransmitter systems—dopaminergic, serotonergic, and cholinergic—are also integral to the neurobiology of apathy. Dopamine plays a crucial role in initiating and sustaining goal-directed behaviors, and hypodopaminergic states are strongly associated with apathy, particularly in Parkinson's disease (Plant et al., 2024). Serotonergic dysfunction has been linked to selective serotonin reuptake inhibitor (SSRI)-induced apathy, a syndrome described in both elderly and younger adults (Padala et al., 2020). Additionally, the cholinergic system's degeneration in Alzheimer's disease contributes to motivational deficits, implicating acetylcholine in the regulation of both attentional and emotional engagement.

Advanced neuroimaging techniques, including positron emission tomography (PET) and functional MRI (fMRI), have provided compelling evidence of distinct neurobiological signatures associated with apathy. For example, Tay et al. (2020) used network neuroscience approaches to reveal that cerebrovascular apathy is associated with reduced connectivity in the default mode and salience networks. These insights have opened the door to biomarker-driven diagnostic tools and potential neurostimulation interventions.

Taken together, the neurobiological findings underscore the notion that apathy is not simply a psychological symptom but a syndrome with discrete neural correlates. Understanding these mechanisms is essential for developing pharmacologic and nonpharmacologic treatments that target the underlying circuitry rather than merely managing the behavioral symptoms.

Fronto-Subcortical Circuits

Research has increasingly demonstrated that apathy arises from dysfunctions in specific brain circuits, especially the fronto-subcortical pathways involving the anterior cingulate cortex (ACC), dorsolateral prefrontal cortex (dlPFC), orbitofrontal cortex (OFC), and the ventral striatum, particularly the nucleus accumbens (Mehak et al., 2023; Morris et al., 2023). These

circuits regulate executive functioning, motivation, and emotional response. Structural and functional imaging studies show that disruptions in these regions, whether due to neurodegenerative disease, vascular injury, or trauma, can precipitate apathy before other cognitive or mood symptoms emerge (Morris et al., 2023; Sankhe et al., 2025).

Neurotransmitter Systems

Dopamine, acetylcholine, and serotonin are the primary neurotransmitters implicated in apathy. Hypodopaminergic states, common in Parkinson's disease, reduce motivation and effort-based decision-making (Plant et al., 2024). Cholinergic deficits, especially in Alzheimer's disease, contribute to attentional and motivational impairment (Mehak et al., 2023). Additionally, excess serotonergic activity—often from SSRI use—can paradoxically lead to apathy, especially in older adults (Padala et al., 2020).

Implications for Treatment

For clinicians, understanding these neurobiological underpinnings guides pharmacological strategies. Rather than defaulting to antidepressants, targeted dopaminergic or cholinergic agents may be considered, depending on the underlying disease and apathy subtype (Naguy et al., 2025).

Assessment and Diagnostic Tools

Understanding apathy as a distinct clinical entity necessitates precise assessment tools and diagnostic clarity. While apathy often overlaps with depression, cognitive decline, or fatigue, its defining features—diminished motivation, reduced goal-directed behavior, and blunted emotional responsiveness—warrant a standalone diagnostic approach.

Diagnostic Criteria for Apathy

Miller et al. (2021) proposed comprehensive diagnostic criteria for apathy in neurocognitive disorders (NCDs), emphasizing the presence of three core domains: diminished initiative, diminished interest, and diminished emotional expression. These symptoms must persist for at least four weeks and cause significant functional impairment. Importantly, these features should not be better explained by other psychiatric, medical, or neurological conditions. The criteria underscore the need to differentiate apathy from similar constructs such as anhedonia, fatigue, or social withdrawal. For instance, anhedonia refers to a reduced ability to experience pleasure and is central to depression, whereas apathy refers to the lack of initiation or interest, regardless of emotional valence.

Common Assessment Scales

Several validated instruments are available for measuring apathy severity and impact. The most widely used include:

- *Apathy Evaluation Scale* (AES) – Assesses cognitive, behavioral, and emotional aspects of apathy based on self-report, clinician rating, or informant input.
- *Neuropsychiatric Inventory* (NPI) Apathy Subscale – Assesses apathy within the broader context of behavioral symptoms in dementia.
- *Apathy-Motivation Index* (AMI) – A brief, self-report scale suitable for both clinical and research settings.
- *Dimensional Apathy Scale* (DAS) – Measures executive, emotional, and initiation apathy separately, offering granularity in profiling.

Sankhe et al. (2025) recently mapped these commonly used scales onto the formal diagnostic criteria established for NCD-related apathy. Their findings support the clinical utility of both the AES and the DAS in reliably identifying and differentiating apathy subtypes.

Apathy Across Disorders

The presentation and prevalence of apathy vary across neurological and psychiatric conditions. For instance, Pallucca et al. (2024) reported that apathy is present in over 30% of post-stroke patients, often worsening functional outcomes and reducing quality of life. In Alzheimer's disease, apathy is one of the most frequent neuropsychiatric symptoms, appearing in early stages and progressing alongside cognitive decline (Mehak et al., 2023).

Peelo et al. (2022) emphasized that apathy in Huntington’s disease often emerges as a three-dimensional construct, with distinct deficits in emotional engagement, cognitive effort, and behavioral activation. Tailored diagnostic frameworks are therefore necessary depending on the underlying etiology.

Cultural and Sociodemographic Considerations

Assessment tools must also account for sociocultural variables and baseline functioning. Nooruddin and Rudra (2025) note that declining engagement with political and economic systems among younger populations may represent broader societal trends of apathy rather than clinical syndromes. Similarly, Zhelnina (2020) describes a "trained apathy" in politically marginalized groups, emphasizing the importance of contextual interpretation.

Cultural norms around emotional expression, motivation, and social engagement must be considered to avoid over-pathologizing normative variations in behavior. Comprehensive evaluation should include collateral interviews and longitudinal tracking.

Clinical Implications

Accurate assessment of apathy is essential for several reasons. First, it enables differentiation from other neuropsychiatric syndromes that require different interventions. Second, it facilitates targeted treatment planning, as pharmacological and nonpharmacological strategies for apathy diverge from those used for depression or cognitive impairment. Finally, understanding the degree and dimensions of apathy can help caregivers and clinicians set realistic goals and measure treatment outcomes over time.

Pharmacological and Nonpharmacological Treatments for Apathy

The management of apathy remains a significant clinical challenge, particularly because the condition is resistant to many standard interventions used for overlapping disorders such as depression or anxiety. Treatment approaches must be tailored based on underlying neurological conditions, apathy subtypes, and patient-specific factors including cognitive status and comorbidities.

Pharmacological Interventions

Despite the lack of FDA-approved treatments specifically for apathy, several pharmacologic strategies have been explored, particularly in the context of neurodegenerative diseases. Clinical trials and observational studies offer cautious optimism, though the evidence remains mixed.

1. *Stimulants and Dopaminergic Agents*:

The use of dopaminergic medications such as methylphenidate has been the most extensively studied in the treatment of apathy, particularly in Alzheimer's disease. The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2) demonstrated that methylphenidate was associated with modest improvements in apathy symptoms (Sankhe

et al., 2025). However, side effects and concerns about overactivation in frail elderly populations remain limiting factors.

2. *Cholinesterase Inhibitors and NMDA Antagonists*:

Cholinesterase inhibitors like donepezil and NMDA receptor antagonists such as memantine have shown limited efficacy in treating apathy, despite their broader use in dementia management (Lanctôt et al., 2023). Their effects on motivation and engagement appear modest and vary depending on the severity and subtype of apathy.

3. *Antidepressants and SSRIs*:

Selective serotonin reuptake inhibitors (SSRIs), commonly prescribed for depression, may paradoxically exacerbate apathy in certain patients. Padala et al. (2020) documented a phenomenon known as SSRI-associated apathy syndrome, particularly in older adults, where apathy symptoms worsened despite improvements in mood.

4. *Emerging Pharmacological Strategies*:

Naguy et al. (2025) emphasize the need for novel pharmacological agents specifically targeting the neurobiological substrates of apathy, such as dopaminergic, serotonergic, and noradrenergic pathways. Ongoing clinical trials (Lanctot, 2023) are exploring novel psychostimulants, glutamatergic modulators, and neuropeptides to address motivation and behavioral initiation.

Nonpharmacological Treatments

In recent years, there has been a growing interest in nonpharmacological interventions, especially in light of the limited efficacy and potential adverse effects of medications in elderly or cognitively impaired populations.

1. *Behavioral Activation and Cognitive Stimulation*:

Manera et al. (2020) proposed a structured framework of nonpharmacological interventions targeting apathy in brain disorders. These include engaging patients in meaningful, goal-directed activities such as art therapy, mindfulness, music therapy, or structured social interaction, all of which can activate emotional and cognitive networks.

2. *Cognitive-Behavioral Therapy (CBT) Approaches*:

Plant et al. (2024) developed a cognitive-behavioral model of apathy in Parkinson's disease, highlighting the role of negative beliefs about capability and outcome. CBT interventions that target these maladaptive cognitions, increase self-efficacy, and promote behavioral initiation can be effective, particularly in early-stage Parkinson's and mild cognitive impairment.

3. *Environmental Enrichment and Occupational Therapy*:

Structured daily routines and environmental cues can enhance behavioral activation. Incorporating occupational therapy and physical activity into daily life has shown promising results in reducing apathy symptoms in institutionalized populations.

4. *Technological Innovations and Virtual Therapies*:

Advancements in digital therapeutics and smart technology have introduced new avenues for remote engagement and apathy management. Examples include gamified cognitive training apps, virtual reality scenarios for social interaction, and digital reminders to initiate tasks.

Cultural and Sociodemographic Considerations

Assessment tools must also account for sociocultural variables and baseline functioning. Nooruddin and Rudra (2025) note that declining engagement with political and economic systems among younger populations may represent broader societal trends of apathy rather than

clinical syndromes. Similarly, Zhelnina (2020) describes a "trained apathy" in politically marginalized groups, emphasizing the importance of contextual interpretation.

Cultural norms around emotional expression, motivation, and social engagement must be considered to avoid over-pathologizing normative variations in behavior. Comprehensive evaluation should include collateral interviews and longitudinal tracking.

For academics and clinicians, it is important to contextualize apathy in cultural and lifespan frameworks. Behaviors that appear apathetic in one culture may be normative in another, and tools should be adapted for different ages and sociocultural backgrounds (Nooruddin & Rudra, 2025; Zhelnina, 2020).

Caregiver Support

Education and support for caregivers are critical, as apathy can increase caregiver stress and risk of burnout. Psychoeducation about apathy's neurological origins and practical guidance for managing symptoms help both caregivers and patients (Pallucca et al., 2024).

Apathy Beyond the Clinic

Apathy is increasingly recognized as a sociocultural phenomenon, not just a clinical syndrome. Political disengagement, declining civic participation, and compassion fatigue reflect a broader "apathy syndrome" at the societal level (Zhelnina, 2020; Wood & Schulman, 2021). These patterns are especially pronounced among marginalized communities who face chronic stress, disenfranchisement, and institutional distrust (Nooruddin & Rudra, 2025).

Cultural Narratives

Cultural attitudes toward emotion and motivation shape both the experience and interpretation of apathy. In some contexts, withdrawal may be adaptive—a response to chronic adversity or cultural norms around emotional restraint (Stoliarov, 2023).

Ethical Care

For clinicians and researchers, ethical care means not overpathologizing healthy or adaptive forms of emotional distance. Assessment and treatment should respect individual and community narratives, honoring the distinction between clinical apathy and existential protest or burnout.

Psychoeducation and Support for Clients and Families

Validating the Experience of Apathy

For clients and their families, understanding that apathy is a neurological or psychological syndrome, rather than a moral failing, is profoundly important (Silva et al., 2021). Psychoeducation should highlight the syndrome's causes, prognosis, and treatment options.

Practical Strategies

Caregivers benefit from training in behavioral prompts, structured routines, and positive feedback. Engagement in meaningful activities—even on a small scale—can interrupt the cycle of withdrawal and reinforce the value of incremental progress (Manera et al., 2020; Pallucca et al., 2024).

Reducing Stigma

By sharing knowledge about the neurobiological basis of apathy, clinicians and advocates can help reduce stigma, encourage early intervention, and foster more compassionate care environments (Manera et al., 2020).

Conclusion

Apathy is a complex, multifaceted syndrome at the intersection of neurobiology, psychology, and society. Advances in neuroimaging, standardized assessment, and evidence-

based interventions are improving outcomes, but ongoing research and cultural sensitivity remain essential. For academics, clinicians, and clients, a nuanced understanding of apathy can enhance diagnosis, inform treatment, and foster hope. Recognizing apathy as both a clinical and social phenomenon is critical for reducing stigma and supporting effective, individualized care.

Conclusion and Future Directions

Apathy, often misunderstood and mischaracterized, stands at the intersection of neuroscience, psychology, culture, and politics. This essay has explored its complex etiology—ranging from the disrupted reward circuits in Alzheimer's and Parkinson's disease, to the pharmacological side effects of SSRIs, and the intricate differences between apathy and depression. We have seen that apathy is not simply a lack of emotion or energy, but a multifaceted condition involving impaired motivation, diminished goal-directed behavior, and a reduced ability to engage meaningfully with life.

At a neurological level, disruptions in the anterior cingulate cortex, basal ganglia, and frontal-striatal networks have been consistently implicated in the manifestation of apathy across a range of neurodegenerative disorders. Clinical research continues to refine diagnostic criteria, such as those proposed by Miller et al. (2021), and to validate assessment tools that more precisely map apathy symptoms (Sankhe et al., 2025). Pharmacological interventions—including dopaminergic agents and stimulant medications—show promise, yet remain limited by heterogeneous efficacy and side effect profiles. Nonpharmacological approaches such as mindfulness, cognitive-behavioral therapy, and goal-setting techniques are emerging as valuable adjuncts, particularly when culturally attuned and individualized.

But apathy cannot be fully understood in biological terms alone. As this essay has emphasized, it must also be seen through the broader lenses of social disenchantment, cultural

conditioning, and philosophical detachment. From the Stoic virtue of apatheia to the political indifference highlighted by Zhelnina (2020) and Nooruddin and Rudra (2025), apathy embodies both pathology and protest. In marginalized communities and overburdened institutions, apathy can signal the limits of resilience—and the need for systemic healing.

Future Directions

As researchers and clinicians move forward, several key directions merit emphasis:

1. *Integration of Multidisciplinary Perspectives*

   Understanding apathy requires a holistic framework that incorporates neurobiology, psychology, sociology, and philosophy. Integrating these fields will enhance diagnostic accuracy, therapeutic efficacy, and cultural competence.

2. *Personalized Treatment Approaches*

   Future interventions must be tailored not only to the neurological profile of the patient but also to their values, cultural context, and life history. This may involve blending pharmacological treatments with narrative therapy, life coaching, or expressive arts.

3. *Community-Based and Preventive Strategies*

   Apathy should be addressed not only in clinical settings but within schools, workplaces, and community organizations. Programs that promote emotional resilience, civic engagement, and social connection may serve as upstream interventions against widespread disengagement.

4. *Ethical Sensitivity and De-Stigmatization*

   Clinicians must remain cautious not to pathologize healthy forms of emotional distance or existential reflection. Distinguishing between apathy as illness and apathy as protest or philosophical stance is critical for ethical care.

5. *Longitudinal and Cross-Cultural Research*

Much of the current literature focuses on Western populations. Expanding studies across diverse global cultures and tracking individuals over time will help delineate universal and culture-bound elements of apathy.

In sum, apathy is a silent but significant force shaping the health and soul of individuals and societies. To address it effectively, we must move beyond narrow definitions and embrace the full complexity of what it means to care—and what it costs when we cease to. By listening more deeply, designing more human-centered systems, and attending to both the brain and the spirit, we may yet transform apathy from a clinical challenge into an opportunity for collective healing and renewal.

References

Lanctôt, K. (2023). Clinical trials for treatment of apathy. *Journal of the Neurological Sciences, 455*, 121025. https://doi.org/10.1016/j.jns.2023.121025

Lanctôt, K. L., Ismail, Z., Bawa, K. K., Cummings, J. L., Husain, M., Mortby, M. E., & Robert, P. (2023). Distinguishing apathy from depression: A review differentiating the behavioral, neuroanatomic, and treatment-related aspects of apathy from depression in neurocognitive disorders. *International Journal of Geriatric Psychiatry, 38*(2), e5882. https://doi.org/10.1002/gps.5882

Ma, L. (2020). Depression, anxiety, and apathy in mild cognitive impairment: Current perspectives. *Frontiers in Aging Neuroscience, 12*, 9. https://doi.org/10.3389/fnagi.2020.00009

Manera, V., Abrahams, S., Agüera-Ortiz, L., Bremond, F., David, R., Fairchild, K., Gros, A., Hanon, C., Husain, M., König, A., Lockwood, P. L., Pino, M., Radakovic, R., Robert, G., Slachevsky, A., Stella, F., Tribouillard, A., Trimarchi, P. D., Verhey, F., … Robert, P. (2020). Recommendations for the nonpharmacological treatment of apathy in brain disorders. *The American Journal of Geriatric Psychiatry, 28*(4), 410–420. https://doi.org/10.1016/j.jagp.2019.07.014

Mehak, S. F., Shivakumar, A. B., Saraf, V., Johansson, M., & Gangadharan, G. (2023). Apathy in Alzheimer's disease: A neurocircuitry based perspective. *Ageing Research Reviews, 87*, 101891. https://doi.org/10.1016/j.arr.2023.101891

Miller, D. S., Robert, P., Ereshefsky, L., Adler, L., Bateman, D., Cummings, J., DeKosky, S. T., Fischer, C. E., Husain, M., Ismail, Z., Jaeger, J., Lerner, A. J., Li, A., Lyketsos, C. G., Manera, V., Mintzer, J., Moebius, H. J., Mortby, M., Meulien, D., … Lanctôt, K. L.

(2021). Diagnostic criteria for apathy in neurocognitive disorders. Alzheimer's & Dementia, 17(12), 1892–1904. https://doi.org/10.1002/alz.12358

Morris, L.-A., Harrison, S. J., Melzer, T. R., Dalrymple-Alford, J. C., Anderson, T. J., MacAskill, M. R., & Le Heron, C. J. (2023). Altered nucleus accumbens functional connectivity precedes apathy in Parkinson's disease. *Brain, 146*(7), 2739–2752. https://doi.org/10.1093/brain/awad113

Naguy, A., Alablani, D. S., Alsalem, N. J., & Alamiri, B. (2025). Psychopharmacology of apathy. *American Journal of Therapeutics*. https://doi.org/10.1097/MJT.0000000000001860

Nooruddin, I., & Rudra, N. (2025). From enthusiasm to apathy: Dwindling support for globalization among future generations. *Journal of International Economic Law, 27*(4), 697–705. https://doi.org/10.1093/jiel/jgae053

Nsor, N., & Brown, C. (2024). Understanding apathy: Behavioral and neural correlates of apathy in neurodegenerative disorders. *Alzheimer's & Dementia, 20*(S8). https://doi.org/10.1002/alz.095685

Padala, P. R., Padala, K. P., Majagi, A. S., Garner, K. K., Dennis, R. A., & Sullivan, D. H. (2020). Selective serotonin reuptake inhibitors-associated apathy syndrome: A cross sectional study. *Medicine (Baltimore), 99*(33), e21497. https://doi.org/10.1097/MD.0000000000021497

Pallucca, C., Lisiecka-Ford, D. M., Wood, L., Abul, A., Jolly, A. A., Tozer, D. J., Bell, S., Forster, A., Morris, R. G., & Markus, H. S. (2024). Apathy after stroke: Incidence, symptom trajectory, and impact on quality of life and disability. *Neurology, 102*(3). https://doi.org/10.1212/WNL.0000000000208052

Peelo, C. G., Fallon, M., Campbell, D., Hammond, M., Hardiman, O., & Pender, N. (2022). F32 Apathy in three dimensions: Incidence and neuropsychological correlates of apathy in HD. *Journal of Neurology, Neurosurgery and Psychiatry, 93*(Suppl 1), A47. https://doi.org/10.1136/jnnp-2022-ehdn.123

Plant, O., Kienast, A., Drew, D. S., Slavkova, E. D., Muhammed, K., Kennerley, H., Husain, M., & Witt, K. (2024). A cognitive-behavioral model of apathy in Parkinson's Disease. *Parkinson's Disease, 2024*(1), 2820257. https://doi.org/10.1155/2024/2820257

Ponthiere, G. (2023). Epictetusian rationality. *Economic Theory*. https://doi.org/10.1007/s00199-023-01530-z

Sankhe, K., Bawa, K. K., Miller, D. S., Bateman, D., Cummings, J. L., Ereshefsky, L., Husain, M., Ismail, Z., Manera, V., Mintzer, J., Moebius, H. J., Mortby, M., Porsteinsson, A., Robert, P., & Lanctôt, K. L. (2025). Mapping of validated apathy scales onto the apathy diagnostic criteria for neurocognitive disorders. *International Psychogeriatrics*, 100074. https://doi.org/10.1016/j.inpsyc.2025.100074

Sankhe, K., Tumati, S., Perin, J., Rivet, L., Vieira, D., Rosenberg, P. B., Herrmann, N., Shade, D., Lerner, A. J., Padala, P. R., Brawman-Mintzer, O., van Dyck, C. H., Porsteinsson, A. P., Craft, S., Levey, A. I., Mintzer, J., & Lanctôt, K. L. (2025). Correlation between changes in apathy and cognition in Alzheimer's disease associated apathy: Analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2). *International Psychogeriatrics, 37*(2), 100012. https://doi.org/10.1016/j.inpsyc.2024.100012

Silva, D., Martins, R., Polido, F., & Cruz, M. D. C. (2021). A closer look to apathy. *European Psychiatry, 64*(S1), S474. https://doi.org/10.1192/j.eurpsy.2021.1266

Stoliarov, A. (2023). Apathy. *Philosophical Anthropology, 9*(1), 177–190. https://doi.org/10.21146/2414-3715-2023-9-1-177-190

Tay, J., Lisiecka-Ford, D. M., Hollocks, M. J., Tuladhar, A. M., Barrick, T. R., Forster, A., O'Sullivan, M. J., Husain, M., de Leeuw, F.-E., Morris, R. G., & Markus, H. S. (2020). Network neuroscience of apathy in cerebrovascular disease. *Progress in Neurobiology, 188*, 101785. https://doi.org/10.1016/j.pneurobio.2020.101785

Wood, S., & Schulman, K. (2021). When vaccine apathy, not hesitancy, drives vaccine disinterest. *JAMA, 325*(24), 2435–2436. https://doi.org/10.1001/jama.2021.7707

Zhelnina, A. (2020). The apathy syndrome: How we are trained not to care about politics. *Social Problems, 67*(2), 358–378. https://doi.org/10.1093/socpro/spz019